Radiology services provider Radiologix continues to outpace analysts’ revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the company’s ninth
Radiology services provider Radiologix continues to outpace analysts revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the companys ninth consecutive quarter of revenue growth. Net income for the quarter was $4 million, compared to net income of $3.7 million on revenues of $37.3 million for the same quarter a year ago. Revenues for the year totaled $181 million, a 33% increase over revenues of $135.6 million in 1998. Net income for the quarter rose 19% to $16 million from $13.5 million in 1998.
Despite the increases, the companys stock continues to hover around $4 per share. The stock reached its peak of nearly $9 per share last September following Radiologixs acquisition of Questar (SCAN 8/18/99). That deal made Radiologix (then known as American Physician Partners) one of the largest operators of imaging centers in the U.S., with 118 sites in 18 states and the District of Columbia.
In related news, Radiologix named former senior vice president and COO Mark Martin president of the Dallas-based company. Martin takes over from Mark Wagar, who continues to serve as chairman and CEO.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.